


Intra-arterial chemo promising for intraocular retinoblastoma

March 21 2016



(HealthDay)—Intra-arterial chemotherapy appears to be promising for

intraocular retinoblastoma, according to a review published online March 17 in *JAMA Ophthalmology*.

Yacoub A. Yousef, M.D., from the Hospital for Sick Children in Toronto, and colleagues conducted a systematic review to summarize the outcomes of intra-arterial [chemotherapy](#). Data were included from 12 publications with discernable nonduplicative information, reporting on 655 patients, 757 eyes, and 2,350 catheterizations.

The researchers found that all reports were single-arm case series, and eight were retrospective. Global salvage was achieved for 66 percent of all eyes across all studies. Chorioretinal atrophy and vascular occlusions were the most common reported toxicities. There were reports of at least 13 [children](#) with metastases; seven additional children had metastases after publication. Comparison of disease severity at presentation was complicated by use of four different classification systems. In most studies, visual outcome was not addressed; no study had a comparative group and consequently meta-analysis was not possible

"Intra-arterial chemotherapy is a promising new treatment associated with high rates of globe salvage," the authors write. "However, the literature is limited by the predominance of retrospective case series, absence of comparison groups, short median follow-up, heterogeneous definitions and tumor classifications, and frequent duplicate reporting."

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2016 [HealthDay](#). All rights reserved.

Citation: Intra-arterial chemo promising for intraocular retinoblastoma (2016, March 21)
retrieved 25 April 2024 from

<https://medicalxpress.com/news/2016-03-intra-arterial-chemo-intraocular-retinoblastoma.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.